CN104812894B - 新型mva病毒及其用途 - Google Patents

新型mva病毒及其用途 Download PDF

Info

Publication number
CN104812894B
CN104812894B CN201280077370.4A CN201280077370A CN104812894B CN 104812894 B CN104812894 B CN 104812894B CN 201280077370 A CN201280077370 A CN 201280077370A CN 104812894 B CN104812894 B CN 104812894B
Authority
CN
China
Prior art keywords
virus
mva
cell
amino acid
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201280077370.4A
Other languages
English (en)
Chinese (zh)
Other versions
CN104812894A (zh
Inventor
英戈·乔丹
福尔克·桑迪希
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ProBioGen AG
Original Assignee
ProBioGen AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ProBioGen AG filed Critical ProBioGen AG
Publication of CN104812894A publication Critical patent/CN104812894A/zh
Application granted granted Critical
Publication of CN104812894B publication Critical patent/CN104812894B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24061—Methods of inactivation or attenuation
    • C12N2710/24064—Methods of inactivation or attenuation by serial passage
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24121—Viruses as such, e.g. new isolates, mutants or their genomic sequences

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201280077370.4A 2012-09-28 2012-09-28 新型mva病毒及其用途 Active CN104812894B (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP2012/069256 WO2014048500A1 (en) 2012-09-28 2012-09-28 Novel mva virus and uses thereof

Publications (2)

Publication Number Publication Date
CN104812894A CN104812894A (zh) 2015-07-29
CN104812894B true CN104812894B (zh) 2021-10-22

Family

ID=46982581

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201280077370.4A Active CN104812894B (zh) 2012-09-28 2012-09-28 新型mva病毒及其用途

Country Status (12)

Country Link
US (1) US9732325B2 (cg-RX-API-DMAC7.html)
EP (1) EP2900810B1 (cg-RX-API-DMAC7.html)
JP (1) JP2015535687A (cg-RX-API-DMAC7.html)
CN (1) CN104812894B (cg-RX-API-DMAC7.html)
AU (1) AU2012391162A1 (cg-RX-API-DMAC7.html)
BR (1) BR112015006798A2 (cg-RX-API-DMAC7.html)
CA (1) CA2885240A1 (cg-RX-API-DMAC7.html)
DK (1) DK2900810T3 (cg-RX-API-DMAC7.html)
IN (1) IN2015DN02335A (cg-RX-API-DMAC7.html)
MX (1) MX2015003687A (cg-RX-API-DMAC7.html)
RU (1) RU2015115898A (cg-RX-API-DMAC7.html)
WO (1) WO2014048500A1 (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3585882A1 (en) 2017-02-23 2020-01-01 ProBioGen AG Novel vaccinia virus vectors related to mva with extensive genomic symmetries
EP3973973A1 (en) 2017-10-31 2022-03-30 KaliVir Immunotherapeutics, Inc. Platform oncolytic vector for systemic delivery
CN108371715A (zh) * 2018-01-03 2018-08-07 肖小林 一种病毒的靶向性防治药物
EP3790579A4 (en) * 2018-05-11 2022-06-15 City of Hope Mva vectors for expressing multiple cytomegalovirus (cmv) antigens and use thereof
EP3818150A1 (en) 2018-07-04 2021-05-12 ProBioGen AG Method for purifying an enveloped virus
AU2021385059A1 (en) 2020-11-19 2023-06-08 Kalivir Immunotherapeutics, Inc. Oncolytic immunotherapy by tumor micro-environment remodeling
WO2023128672A1 (ko) * 2021-12-29 2023-07-06 재단법인 아산사회복지재단 외피외 바이러스 생산이 증가한 신규한 백시니아 바이러스 변이주
WO2023223183A1 (en) 2022-05-16 2023-11-23 Crispr Therapeutics Ag Picornaviral vectors for gene editing

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7645456B2 (en) * 2001-04-23 2010-01-12 Sanofi Pasteur Biologics Co. Vaccinia virus strains
JP5052893B2 (ja) 2003-02-20 2012-10-17 アメリカ合衆国 ポックスベクターにおける新規の挿入部位

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
A chemically defined production process for highly attenuated poxviruses;Ingo Jordan，et al;《Biologicals》;20101128;第39卷(第1期);第50-58页 *
An avian cell line designed for production of highly attenuated viruses;Jordan，et al;《Vaccine》;20090129;第27卷(第5期);全文 *
Resistance of a vaccinia virus A34R deletion mutant to spontaneous rupture of the outer membrane of progeny virions on the surface of infected cells;Husain，et al;《Virology》;20070914;第336卷(第2期);全文 *

Also Published As

Publication number Publication date
US9732325B2 (en) 2017-08-15
CA2885240A1 (en) 2014-04-03
IN2015DN02335A (cg-RX-API-DMAC7.html) 2015-08-28
MX2015003687A (es) 2015-06-15
DK2900810T3 (en) 2019-04-29
US20150299666A1 (en) 2015-10-22
AU2012391162A1 (en) 2015-04-09
WO2014048500A1 (en) 2014-04-03
BR112015006798A2 (pt) 2017-11-21
JP2015535687A (ja) 2015-12-17
EP2900810A1 (en) 2015-08-05
EP2900810B1 (en) 2019-02-20
CN104812894A (zh) 2015-07-29
RU2015115898A (ru) 2016-11-20

Similar Documents

Publication Publication Date Title
CN104812894B (zh) 新型mva病毒及其用途
CN1934243B (zh) 用于病毒生产的永生化的禽类细胞系
JP5783642B2 (ja) Ｍｖａの主なゲノム欠失を含むワクシニアウイルス変異体
EP0515433A1 (en) Recombinant poxvirus internal cores.
US20040265986A1 (en) Method for the recovery and purification of poxviruses from infected cells
JP2004535203A (ja) ウイルス増殖方法
Jordan et al. A chemically defined production process for highly attenuated poxviruses
Léon et al. The EB66® cell line as a valuable cell substrate for MVA-based vaccines production
CN1723285B (zh) 重组的mva及其产生方法
Melamed et al. Attenuation and immunogenicity of host-range extended modified vaccinia virus Ankara recombinants
AU2009201629B2 (en) Production of ALVAC on avian embryonic stem cells
US11104884B2 (en) Vaccinia virus vectors related to MVA with extensive genomic symmetries
KR20250156704A (ko) 메추라기 세포 배양을 통한 폭스바이러스 생산
WO2024188801A1 (en) Use of quail cell lines for poxvirus production
AU2024236322A1 (en) Methods of isolating poxviruses from avian cell cultures
MX2013001772A (es) Linea celular de amniocitos humanos permanente para la produccion de virus de influenza.
JP2019187249A (ja) 増殖性ヘルパーワクシニアウイルスを使用するポックスウイルスの製造方法

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
EXSB Decision made by sipo to initiate substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant